Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estradiol Valerate/Dienogest for Dysfunctional Uterine Bleeding
NCT00293059Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2005
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in dysfunctional uterine bleeding (DUB) comparing Estradiol valerate/Dienogest with Placebo (2 arms). Primary endpoint: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms at 90 days. Started Dec 2005; status: completed.
02
Drugs
estradiol valerate + dienogest
03
Conditions
dysfunctional uterine bleeding (DUB)
Beyond the preview
Go deeper on NCT00293059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293059.